Sittner & Nelson’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1
| Closed | – | – | 544 |
|
|
2025
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 514 |
|
|
2025
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 515 |
|
|
2025
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 522 |
|
|
2024
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 506 |
|
|
2024
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 468 |
|
|
2024
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 510 |
|
|
2024
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 514 |
|
|
2023
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 487 |
|
|
2023
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 489 |
|
|
2023
Q2 | $1 | Hold |
1
| – | – | ﹤0.01% | 485 |
|
|
2023
Q1 | $2 | Hold |
1
| – | – | ﹤0.01% | 490 |
|
|
2022
Q4 | $3 | Hold |
1
| – | – | ﹤0.01% | 462 |
|
|
2022
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 500 |
|
|
2022
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 496 |
|
|
2022
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 461 |
|
|
2021
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 452 |
|
|
2021
Q3 | $1K | Hold |
1
| – | – | ﹤0.01% | 407 |
|
|
2021
Q2 | $1K | Hold |
1
| – | – | ﹤0.01% | 383 |
|
|
2021
Q1 | $2K | Hold |
1
| – | – | ﹤0.01% | 375 |
|
|
2020
Q4 | $2K | Buy |
+1
| New | +$2.05K | ﹤0.01% | 400 |
|
Sittner & Nelson's BXRX Position: Q4 2025 in Review
Sittner & Nelson sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2025, closing a stake of 1 share.
Sittner & Nelson first reported a position in BXRX in Q4 2020 and held it in 20 quarters. The position peaked at $2K in Q1 2021. 0 funds tracked by Wall St. Rank hold BXRX as of Q4 2025.
- Sittner & Nelson reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2025 after selling out during the quarter.
- Sittner & Nelson sold 1 Baudax Bio, Inc. Common Stock share in Q4 2025.
- Sittner & Nelson first reported a position in Baudax Bio, Inc. Common Stock in Q4 2020 and held it in 20 quarters.
- Sittner & Nelson's Baudax Bio, Inc. Common Stock position peaked at $2K in Q1 2021.
- 0 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2025.
Based on Sittner & Nelson's 13F filing for Q4 2025, filed 11 Feb 2026.